# A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients

> **NCT02601287** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 168 (actual)

## Conditions studied

- Urinary Incontinence
- Overactive Bladder

## Interventions

- **BIOLOGICAL:** Botulinum Toxin Type A

## Key facts

- **NCT ID:** NCT02601287
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2016-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02601287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02601287, "A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02601287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*